We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

59 hedge funds and large institutions have $67.4M invested in Arbutus Biopharma in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more capital invested

Capital invested by funds: $29.7M → $67.4M (+$37.8M)

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

7% more funds holding

Funds holding: 55 → 59 (+4)

4.82% more ownership

Funds ownership: 34.24% → 39.07% (+4.8%)

44% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 18

Holders
59
Holders Change
+4
Holders Change %
+7.27%
% of All Funds
1.16%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
10
Reduced
18
Closed
11
Calls
$501K
Puts
–
Net Calls
+$501K
Net Calls Change
+$509K

Top Buyers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management IV
California
+$5.99M
2
Jennison Associates
Jennison Associates
New York
+$3.53M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$3.07M
4
CAC
Cowen and Company
New York
+$1.5M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$464K

Top Sellers

Rank Fund Capital Flow
1
Primecap Management
Primecap Management
California
-$5.57M
2
BlackRock
BlackRock
New York
-$922K
3
SFM
Sphera Funds Management
Israel
-$763K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$469K
5
Renaissance Technologies
Renaissance Technologies
New York
-$257K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$153K +$89K +54,993 New
HF
27
HRT Financial
New York
$124K +$72.6K +44,892 New
Simplex Trading
28
Simplex Trading
Illinois
$120K +$69.5K +42,925 +10,245%
WG
29
Winton Group
United Kingdom
$118K -$64K -39,555 -48%
Mackenzie Financial
30
Mackenzie Financial
Ontario, Canada
$111K – – –
ECM
31
ExodusPoint Capital Management
New York
$102K -$5.08K -3,141 -8%
OAM
32
Oxford Asset Management
United Kingdom
$61K +$35.7K +22,051 New
BFM
33
Boothbay Fund Management
New York
$59K +$34.4K +21,261 New
PP
34
Paloma Partners
Connecticut
$55K +$31.8K +19,674 New
SC
35
Scotia Capital
Ontario, Canada
$32K -$12.9K -8,000 -41%
State Street
36
State Street
Massachusetts
$32K – – –
ARTA
37
A.R.T. Advisors
New York
$30K -$17.6K -10,894 -50%
SAM
38
Secure Asset Management
Michigan
$28K +$16.2K +10,000 New
Bank of America
39
Bank of America
North Carolina
$25K -$148K -91,331 -91%
Citigroup
40
Citigroup
New York
$16K -$3.51K -2,168 -27%
SIAP
41
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$11K – – –
Wells Fargo
42
Wells Fargo
California
$8K – – –
Deutsche Bank
43
Deutsche Bank
Germany
$4K -$21.1K -13,070 -88%
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$3K -$9.66K -5,969 -82%
HIA
45
Harbor Investment Advisory
Maryland
$3K +$1.62K +1,000 New
FDCDDQ
46
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.22K – – –
CSS
47
Cubist Systematic Strategies
Connecticut
$2K +$1.45K +895 New
PAM
48
Panagora Asset Management
Massachusetts
$1K -$3.09K -1,911 -85%
Barclays
49
Barclays
United Kingdom
$1K -$1.17K -723 -67%
AG
50
Advisor Group
Arizona
$1K – – –
1
2
3

ABUS Hedge Fund Activity: Q4 2019 in Review

59 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2019, worth a combined $67.4M — up 127% from $29.7M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ABUS positions and 11 closed out — a net gain of 4 holders — while 10 added to existing stakes and 18 trimmed.

The largest buyer was Foresite Capital Management IV, opening a new position worth an estimated $5.99M. The largest seller was Primecap Management, cutting an estimated $5.57M.

  • 59 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2019, up from 55 in Q3 2019.
  • Funds reported $67.4M of Arbutus Biopharma stock for Q4 2019, up 127% quarter-over-quarter.
  • 15 funds opened new Arbutus Biopharma positions in Q4 2019 and 11 closed out, a net change of +4 holders.
  • The largest Arbutus Biopharma buyer in Q4 2019 was Foresite Capital Management IV, an estimated $5.99M added.
  • The largest Arbutus Biopharma seller in Q4 2019 was Primecap Management, an estimated $5.57M sold.

Based on aggregated 13F filings for Q4 2019.